• Explore /
  • Poster
  • / An open label, single-arm, two-stage, multicenter, phase II study to evaluate the efficacy and safety of TLC388 as second-line treatment in subjects with poorly differentiated neuroendocrine carcinomas (TCOGT1Z14).

An open label, single-arm, two-stage, multicenter, phase II study to evaluate the efficacy and safety of TLC388 as second-line treatment in subjects with poorly differentiated neuroendocrine carcinomas (TCOGT1Z14).

Abstract Poster

Authors

null

Ming-Huang Chen

Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan

Ming-Huang Chen , Wen-Chi Chou , Chin-Fu Hsiao , Yi-Chang Liu , Chiun Hsu , Shan Yanshen , Yi-Ping Hung , Chia-Hsun Hsieh , Chao-Hua Chiu , Ta-Chih Liu , Shih-Feng Cho , Tsang-Wu Liu , Yee Chao

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Neuroendocrine/Carcinoid

Clinical Trial Registration Number

NCT02457273

Citation

J Clin Oncol 37, 2019 (suppl; abstr 4101)

DOI

10.1200/JCO.2019.37.15_suppl.4101

Abstract #

4101

Poster Bd #

206

Abstract Disclosures

Similar Posters

First Author: Mairead Geraldine McNamara

First Author: Ting Han

First Author: Dawei Chen

First Author: Emmanuelle Samalin